The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Iron Deficiency Anemia Therapy Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The iron deficiency anemia therapy market size has experienced robust expansion over recent years. This market is projected to expand from $4.78 billion in 2025 to $5.15 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Historically, this expansion has been driven by several factors, including the increasing incidence of iron deficiency anemia, greater understanding of anemia management, the broadening of hospital-based treatment guidelines, a rise in the adoption of oral iron supplements, and enhanced diagnostic methods for anemia.
The iron deficiency anemia therapy market is anticipated to experience significant growth in the upcoming years. It is projected to expand to $6.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. The expansion during the forecast period is primarily driven by an increasing need for faster anemia correction, the rising incidence of chronic diseases that lead to anemia, the proliferation of specialty anemia clinics, an amplified focus on maternal and pediatric anemia care, and advancements in iron formulation technologies. Major developments expected within this period include a greater adoption of intravenous iron therapies, a heightened demand for targeted anemia treatments, an increasing emphasis on patient-specific therapy regimens, the broadened availability of oral and parenteral combination therapies, and a strengthened focus on treatment efficacy and safety.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24265&type=smp
Which Significant Factors Are Encouraging Growth In The Iron Deficiency Anemia Therapy Market?
The iron deficiency anemia therapy market is anticipated to expand due to a rising number of chronic disease cases in the future. Chronic diseases refer to medical conditions that are long-lasting, typically enduring for a year or more. The increase in these conditions is attributable to the growing prevalence of unhealthy lifestyles, including poor diet, lack of physical activity, and smoking, which contribute to conditions like obesity, diabetes, and heart disease, resulting in prolonged health complications. Chronic illnesses can heighten the demand for iron deficiency anemia therapy by impairing the body’s proper iron absorption, thereby elevating the likelihood of iron deficiency and making supplementation or treatment essential to normalize iron levels. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia in 2023, or pre-diabetes, marking an 18% increase from 3,065,825 cases in 2022. Consequently, the growing incidence of chronic diseases is fueling the expansion of the iron deficiency anemia therapy market.
What Segment Categories Are Evaluated In The Iron Deficiency Anemia Therapy Market Study?
The iron deficiency anemia therapy market covered in this report is segmented –
1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users
Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations
What Trends Are Impacting The Iron Deficiency Anemia Therapy Market?
Leading companies in the iron deficiency anemia therapy market are concentrating on advancing treatment options, such as injectable formulations, to enhance both efficacy and accessibility. A new injectable formulation refers to a recently developed or modified drug version administered via injection. For example, in May 2023, Emcure Pharmaceuticals Ltd., an Indian pharmaceutical company, launched Orofer FCM 750, a ferric carboxymaltose (FCM) formulation designed for treating iron deficiency and iron deficiency anemia (IDA). Its advantages include improved patient compliance due to less frequent administration compared to oral supplements. The product aims to effectively treat iron deficiency anemia, particularly in individuals who cannot tolerate oral iron supplements. This 750 mg/15 ml injectable ferric carboxymaltose has been approved by India’s DCGI for iron deficiency anemia (IDA) in patients unresponsive to oral iron, specifically pregnant women with hemoglobin <10 g/dl and weighing 35–70 kg, offering a 15-minute infusion (diluted in saline) and aligning with Anemia Mukt Bharat guidelines as a first-line treatment for severe cases.
Who Are The Key Market Participants In The Iron Deficiency Anemia Therapy Market?
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd.
Access The Complete Iron Deficiency Anemia Therapy Market Report:
Which Region Is The Dominant Market In The Iron Deficiency Anemia Therapy Market?
North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Iron Deficiency Anemia Therapy Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Iron Deficiency Anemia Therapy Market 2026, By The Business Research Company
Hemochromatosis Iron Overload Disease Treatment Market Report 2026
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model